[Experimental study of therapy effects of anti -VEGF antibody on osteosarcoma].
OBJECTIVE
To investigate the effect of anti-VEGF antibody on angiogenesis induced by osteosarcoma OS-732 cell line and tumor growth.


METHODS
With a tumor model on the chick embryo chorioallantoic membrane (CAM), the inhibition of angiogenesis and tumor growth by anti-VEGF antibody were observed under a stero-microscope and a light microscope. Furthermore, the proliferation and apoptosis in tumor cells and endothelial cells (EC) were studied by TdT-mediated duTP nick and labeling (TUNEL) and immunohistochemical staining using proliferating cell nuclear antigen (PCNA) monoclonal antibody.


RESULTS
VEGF polyclonal antibody administration in tumor-bearing chick embryo resulted in growth arrest of xenografts and a markedly reduction in the new capillaries which converged upon the tumor. The tumor cell apoptotic index was higher in the anti-VEGF antibody treated group than the negative control group, but the proliferation index was not significantly different between them. At the same time, increased apoptosis and decreased proliferation in EC were also noted.


CONCLUSIONS
VEGF polyclonal antibody is able to inhibit the angiogenesis induced by OS-732 obviously, probably by the mechanism of inhibition of EC proliferation and promotion of their apoptosis, furtherly, which may contribute to the apoptosis of tumor cells and result in suppression of tumor growth.
Li
Yingjia
Y
Department of Ultrasound Diagnosis, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Wang
Dong
D
Gao
Fengxun
F
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D017209:Apoptosis; D001859:Bone Neoplasms / Q000628:therapy*; D002455:Cell Division / Q000187:drug effects; D002642:Chick Embryo; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000276:immunology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D007167:Immunotherapy; D008222:Lymphokines / Q000276:immunology*; D008853:Microscopy; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D012516:Osteosarcoma / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000906:Antibodies; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors